LyGenesis For Profit

Prellis Biologics is building human tissues for drug development, and ultimately, developing human organs for transplantation.
Technology: Organ Engineering
Industry: Regenerative medicine
Headquarters: United States
Investors Number: 1
Total Funding: $14.4M
Estimated Revenue: $1M to $10M
Last Funding Type: Series B

Visit Website
info@lygenesis.com
Register and Claim Ownership